| Literature DB >> 31969152 |
Chen Zhang1, Zheren Tan1, Fafa Tian2.
Abstract
BACKGROUND: Cryptococcal meningitis (CM) is the most common fungal infection of the central nervous system and has high morbidity and mortality. Almost studies about prognostic factors have largely focused on the immunocompromised population rather than immunocompetent patients. So that we sought to conduct a retrospective study to determine prognostic factors which predict the outcomes in immunocompetent patients with CM.Entities:
Keywords: Clinical features; Cryptococcal meningitis; HIV negative; Immunocompetent patients; Prognostic factors
Mesh:
Substances:
Year: 2020 PMID: 31969152 PMCID: PMC6975048 DOI: 10.1186/s12879-020-4794-5
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and clinical profile of apparently immunocompetent patients with Cryptococcal meningitis
| Variable | Value |
|---|---|
| Gender, M/F | 50/26 (66%/34%) |
| Age at onset (years) | 50.0 (40–62) |
| interval from onset to antifungal treatment (day) | 29 (15,40) |
| duration of antifungal treatment (day) | 31 (12.5, 54.5) |
| Am B administration | 69 (90.8%) |
| Shunt surgery | 11 (14.5%) |
| Main symptoms and signs | |
| Headache | 71 (93.4%) |
| Fever | 48 (63.2%) |
| Vomiting | 38 (50.0%) |
| Impaired consciousness | 15 (19.7%) |
| Visual disturbance | 15 (19.7%) |
| Seizures | 9 (11.8%) |
| Limb weakness | 7 (9.2%) |
| Altered mentation | 7 (9.2%) |
| Hearing impairment | 2 (2.6%) |
| Meningeal irritation positive | 45 (59.2%) |
Data are n (%) or median (interquartile range); Am B Amphotericin B, WBC White blood cell, CSF Cerebrospinal fluid
laboratorial findings and Neuroimaging of apparently immunocompetent patients with Cryptococcal meningitis
| Variable | Value |
|---|---|
| Blood WBC count(109/L) | 8.4 (6.6, 11.8) |
| CSF | |
| Opening pressure(>180mmH2O) | 65 (85.5%) |
| WBC count(106/L) | 50 (18.5, 122.5) |
| Elevated WBC counts | 69 (90.8%) |
| Glucose (mmol/L) | 1.66 (0.80, 2.85) |
| Increased glucose level | 56 (73.7%) |
| Chloride (mmol/L) | 117.0 (113.7, 120.3) |
| Increased chloride level | 55 (72.4%) |
| Protein (g/L) | 0.85 (0.54, 1.57) |
| Increased protein level | 62 (81.6%) |
| India ink test positive | 66 (86.8%) |
| Culture positive | 37 (48.7%) |
| Neuroimaging | |
| Dilated Virchow-Robin spaces | 50 (65.8%) |
| Parenchymal lesions | 41 (53.9%) |
| meningeal enhancement | 16 (21.1%) |
| Hydrocephalus | 11 (14.5%) |
| Gelatinous pseudocyst | 7 (9.2%) |
Data are n (%) or median (interquartile range); Am B Amphotericin B, WBC White blood cell, CSF Cerebrospinal fluid
Fig. 1Neuroimaging characters of patients with cryptococcal meningitis. a T2-W image shows multiple dilated Virchow-Robin spaces (black arrow) in basal ganglia; b Abnormality (black arrow) on FLAIR image within the occipital lobe and corpus callosum; c T2-W image shows a gelatinous pseudocyst (black arrow) in basal ganglia; d hydrocephalus on T2-W image; e Contrast-enhanced image shows meningeal enhancement (black arrow) in cerebellum
Results of univariate analysis identifying variables that differed significantly between the good and unfavorable outcome groups
| Quantitative variable | Good ( | Unfavorable ( | |
|---|---|---|---|
| T-test | |||
| Age at onset (years) | 45.63 ± 13.80 | 52.24 ± 15.20 | 0.052 |
| CSF opening pressure (mmH2O) | 290.46 ± 108.24 | 328.05 ± 119.80 | 0.158 |
| Rank sum test | |||
| Interval from onset to antifungal treatment (day) | 30.27 ± 25.65 | 38.69 ± 38.42 | 0.223 |
| Duration of antifungal treatment (day) | 41.61 ± 36.85 | 32.81 ± 26.43 | 0.346 |
| Blood WBC count(109/L) | 8.96 ± 4.06 | 10.04 ± 3.85 | 0.177 |
| CSF WBC count(106/L) | 92.71 ± 80.54 | 77.39 ± 104.71 | 0.104 |
| CSF Glucose (mmol/L) | 2.43 ± 1.22 | 1.54 ± 1.32 | 0.001 |
| CSF Chloride (mmol/L) | 117.34 ± 4.82 | 115.81 ± 9.70 | 0.794 |
| CSF Protein (g/L) | 0.96 ± 0.52 | 1.25 ± 0.93 | 0.673 |
Quantitative results are expressed as the mean ± standard deviation. CSF Cerebrospinal fluid
Analysis identifying qualitative variables that differed significantly between the good and unfavorable outcome groups
| Qualitative variables | Good ( | Unfavorable ( | |
|---|---|---|---|
| Gender (male) | 23 | 27 | 0.990 |
| Am B administration | 33 | 36 | 0.565 |
| Shunt surgery | 2 | 9 | 0.045 |
| Headache | 34 | 37 | 0.456 |
| Fever | 23 | 25 | 0.669 |
| Vomiting | 19 | 19 | 0.490 |
| Impaired consciousness | 1 | 14 | 0.001 |
| Visual disturbance | 5 | 10 | 0.270 |
| Seizures | 1 | 8 | 0.065 |
| Limb weakness | 3 | 4 | 1.000 |
| Altered mentation | 2 | 5 | 0.565 |
| Hearing impairment | 1 | 1 | 0.910 |
| CSF Opening pressure(>300mmH2O) | 13 | 25 | 0.038 |
| Meningeal irritation positive | 17 | 28 | 0.081 |
| India ink test and culture positive | 15 | 11 | 0.142 |
| Dilated VRS | 23 | 27 | 0.990 |
| Parenchymal lesions | 19 | 22 | 0.956 |
| Meningeal enhancement | 6 | 10 | 0.440 |
| Hydrocephalus | 2 | 9 | 0.045 |
| Gelatinous pseudocyst | 3 | 4 | 1.000 |
Pearson’s χ2 continuity correction of Fisher’s exact test was used for statistical analysis; CSF Cerebrospinal fluid
Results of backward stepwise multiple logistic regression analysis of variables that differed significantly between the good and unfavorable outcome groups
| Variable | Engel classification | |
|---|---|---|
| Regression coefficient | ||
| CSF Glucose | −0.575 | 0.012 |
| Impaired consciousness | 2.683 | 0.015 |
| Constant | 0.779 | 0.130 |
CSF Cerebrospinal fluid